Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2020) 70 EP148 | DOI: 10.1530/endoabs.70.EP148

ECE2020 ePoster Presentations Diabetes, Obesity, Metabolism and Nutrition (142 abstracts)

Study on glutamic acid decarboxylase antibodies (Anti–GAD) in blood serum for early diagnosis of diabetes mellitus

Zafar Ibragimov 1 , Timur Alimov 2 , Nigora Maksutova 3 , Elvira Ibragimova 1 , Khamid Karimov 2 , Tokhir Ishanhodjaev 1 , Sanobarkhon Irgasheva 1 & Talat Saatov 1


1Institute of Biophysics and Biochemistry, Mirzo Ulugbek National University of Uzbekistan, Biochemistry, Tashkent, Uzbekistan; 2Institute of Hematology and Blood Transfusion, Uzbekistan Public Healthcare Ministry, Molecular Medicine and Cell Technologies, Tashkent, Uzbekistan; 3Ya.Kh. Turakulov Center for the Scientific and Clinical Study of Endocrinology, Uzbekistan Public Healthcare Ministry, Tashkent, Uzbekistan


There are three main types of diabetes mellitus: type 1 diabetes mellitus (T1DM), type 2 diabetes mellitus (T2DM) and gestational diabetes, with the first two types making about 99% of cases.

According to its nature, type 1 diabetes mellitus (T1DM) is considered as a typical autoimmune disorder characterized with specific autoantibodies. Immunological markers of the diabetes mellitus onset can be found not only in T1DM with its specific clinical picture, but also in T2DM. Glutamic acid decarboxylase antibodies (Anti–GAD) are a DM immunological marker both of clinical and academic interest.

The work was initiated to study predictive value of specific glutamic acid decarboxylase antibodies as the immunological marker.

Anti–GAD concentrations were measured in the blood serum of a proband, a patient with type 1 diabetes mellitus. The enzyme–linked immunosorbent assay with the ELISA kit for Anti–Glutamic Acid Decarboxylase Antibody (Anti–GAD) (Cloud–Clone Corp., Houston, USA) was used for Anti–GAD qualitative determination in plasma and blood serum of the patients. Variation statistics was used for statistical processing of the results.

Anti–GAD concentrations in the probands’ blood were found to be 1.54 times higher than those in blood of the apparently healthy controls (P1 < 0.0001). The similar picture could be seen after examination of a proband’s family members with Anti–GAD concentrations 1.9 times higher than those in the controls. Among other things, this seemed to be associated with the presence of the diabetics among the probands’ family members. It can be explained by the genetic predisposition to DM onset and progression in some family members as well.

Identification of Anti–GAD in patients with the diagnosed DM, as well as in some of their close relatives can serve as a confirmation of predictive value of the immunological marker.

Volume 70

22nd European Congress of Endocrinology

Online
05 Sep 2020 - 09 Sep 2020

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.